A final report for KarXT (xanomeline tartrate/trospium chloride) has been published by influential US pricing watchdog The Institute for Clinical and Economic Review (ICER).
The Boston, USA-based group has issued its report into the schizophrenia med, developed by Karuna Therapeutics (Nasdaq: KRTX), following a public meeting in February.
The document outlines what it sees as the current evidence on effectiveness, noting what it regards as a fair pricing framework for KarXT, as used for adults with schizophrenia who are not considered to have a treatment-resistant condition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze